3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Leukemia, Promyelocytic, Acute
5
Thrombocytopenia
2
Pathologic Complete Response
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Lung Neoplasms
2
Leukemia
2
Hematologic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Cervical Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Primary Myelofibrosis
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Oligometastatic Disease
1
Oligodendroglioma
1
Neoplasms
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Leukemia, Myeloid, Acute
1
Leiomyosarcoma
1
Laryngeal Neoplasms
1
Hypopharyngeal Neoplasms
1
Hematologic Diseases
1
Head and Neck Neoplasms
1
HER2 Negative Breast Cancer
1
Glioma
1
Interventions
Dexamethasone
238
Lenalidomide
145
daratumumab
123
Bortezomib
101
pomalidomide
86
Calcium Dobesilate
76
carfilzomib
74
Cyclophosphamide
70
Specimen Handling
42
isatuximab
40
Biopsy
40
fludarabine
36
belantamab mafodotin
36
Magnetic Resonance Spectroscopy
35
talquetamab
29
dexamethasone acetate
27
dexamethasone 21-phosphate
27
Melphalan
27
auricularum
26
iberdomide
25
ixazomib
22
fludarabine phosphate
22
selinexor
21
elotuzumab
21
Whole-Body Irradiation
14
X-Rays
13
tocilizumab
12
venetoclax
11
Mycophenolic Acid
10
trametinib
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Multiple Myeloma
×
Tretinoin
×
1 year
×
Clear all
NCT06536413
2026-04-03
ATRA
The Methodist Hospital Research Institute
Phase 1/2
Recruiting
42 enrolled